| Verifiedfields: | changed |
| Verifiedrevid: | 457140599 |
| Width: | 250 |
| Usan: | Arformoterol tartrate |
| Tradename: | Brovana |
| Dailymedid: | Arformoterol |
| Routes Of Administration: | Inhalation |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Protein Bound: | 52–65% |
| Elimination Half-Life: | 26 hours |
| Cas Number: | 67346-49-0 |
| Pubchem: | 3083544 |
| Iuphar Ligand: | 7479 |
| Drugbank: | DB01274 |
| Chemspiderid: | 2340731 |
| Unii: | F91H02EBWT |
| Kegg: | D07463 |
| Kegg2: | D02981 |
| Chebi: | 408174 |
| Chembl: | 1201137 |
| Iupac Name: | N-[2-hydroxy-5-[(1''R'')-1-hydroxy-2-[[(2''R'')-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide |
| C: | 19 |
| H: | 24 |
| N: | 2 |
| O: | 4 |
| Stdinchi: | 1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1 |
| Stdinchikey: | BPZSYCZIITTYBL-YJYMSZOUSA-N |
Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).[2]
It is a long-acting β2 adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol. It was approved for medical use in the United States in October 2006. It is available as a generic medication.[3]
Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD).